Evidence map›Paper›PMID 31132294›Full record

ArticleMedical science monitor : international medical journal of experimental and clinical research2019

Identification of a Combined RNA Prognostic Signature in Adenocarcinoma of the Lung.

Si-Yu He, Wen-Jing Xi, Xin Wang, Chao-Han Xu, Liang Cheng, Si-Yao Liu, Qian-Qian Meng, Boyan Li, Yahui Wang, Hong-Bo Shi and 2 more

Open access · greenAbstract read
In one paragraph

Article in Medical science monitor : international medical journal of experimental and clinical research, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.3field-weighted citation impact, top 48% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 8 citations in OpenAlex.

  1. Observational
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 2 institutions in 1 country.

Si-Yu HeCollege of Bioinformatics Science and Technology, Harbin Medical University, Harbin, Heilongjiang, China (mainland).
Wen-Jing XiCollege of Bioinformatics Science and Technology, Harbin Medical University, Harbin, Heilongjiang, China (mainland).
Xin WangCollege of Bioinformatics Science and Technology, Harbin Medical University, Harbin, Heilongjiang, China (mainland).
Chao-Han XuCollege of Bioinformatics Science and Technology, Harbin Medical University, Harbin, Heilongjiang, China (mainland).
Liang ChengCollege of Bioinformatics Science and Technology, Harbin Medical University, Harbin, Heilongjiang, China (mainland).
Si-Yao LiuCollege of Bioinformatics Science and Technology, Harbin Medical University, Harbin, Heilongjiang, China (mainland).
Qian-Qian MengCollege of Bioinformatics Science and Technology, Harbin Medical University, Harbin, Heilongjiang, China (mainland).
Boyan LiCollege of Bioinformatics Science and Technology, Harbin Medical University, Harbin, Heilongjiang, China (mainland).
Yahui WangCollege of Bioinformatics Science and Technology, Harbin Medical University, Harbin, Heilongjiang, China (mainland).
Hong-Bo ShiCollege of Bioinformatics Science and Technology, Harbin Medical University, Harbin, Heilongjiang, China (mainland).
Hong-Jiu WangCollege of Science, Heilongjiang University of Science and Technology, Harbin, Heilongjiang, China (mainland).
Zhen-Zhen WangCollege of Bioinformatics Science and Technology, Harbin Medical University, Harbin, Heilongjiang, China (mainland).
Harbin Medical University · CNHeilongjiang University of Science and Technology · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND Adenocarcinoma of the lung is a type of non-small cell lung cancer (NSCLC). Clinical outcome is associated with tumor grade, stage, and subtype. This study aimed to identify RNA expression profiles, including long noncoding RNA (lncRNA), microRNA (miRNA), and mRNA, associated with clinical outcome in adenocarcinoma of the lung using bioinformatics data. MATERIAL AND METHODS The miRNA and mRNA expression profiles were downloaded from The Cancer Genome Atlas (TCGA) database, and lncRNA expression profiles were downloaded from The Atlas of Noncoding RNAs in Cancer (TANRIC) database. The independent dataset, the Gene Expression Omnibus (GEO) accession dataset, GSE81089, was used. RNA expression profiles were used to identify comprehensive prognostic RNA signatures based on patient survival time. RESULTS From 7,704 lncRNAs, 787 miRNAs, and 28,937 mRNAs of 449 patients, four joint RNA molecular signatures were identified, including RP11-909N17.2, RP11-14N7.2 (lncRNAs), MIR139 (miRNA), KLHDC8B (mRNA). The random forest (RF) classifier was used to test the prediction ability of patient survival risk and showed a good predictive accuracy of 71% and also showed a significant difference in overall survival (log-rank P=0.0002; HR, 3.54; 95% CI, 1.74-7.19). The combined RNA signature also showed good performance in the identification of patient survival in the validation and independent datasets. CONCLUSIONS This study identified four RNA sequences as a prognostic molecular signature in adenocarcinoma of the lung, which may also provide an increased understanding of the molecular mechanisms underlying the pathogenesis of this malignancy.

Indexed as

AdenocarcinomaAdenocarcinoma of LungCarcinoma, Non-Small-Cell LungDatabases, GeneticFemaleGene Expression ProfilingGene Expression Regulation, NeoplasticHumansKaplan-Meier EstimateLung NeoplasmsMaleMicroRNAsPrognosisProportional Hazards ModelsRNA, Long NoncodingRNA, MessengerMicroRNAsRNA, Long NoncodingRNA, Messenger

Identifiers

PMID31132294
PMCPMC6556069
OpenAlexW2946910237

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.